Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2400080184Phase 4Recruiting
Phase 4, randomised, open-label trial of esketamine in postpartum depression (PPD) and mental disorder (8 arms), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Postpartum depression incidence assessed by Edinburgh Postnatal Depression Scale. Started Jan 2024; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2400080184.